ORIGINAL ARTICLE

In vitro screening of blood-brain barrier penetration of clinically used acetylcholinesterase reactivators

Jana Žďárová Karasová1, Petr Stodůlka2, Kamil Kuča1,2

1Department of Toxicology, 2Center of Advanced Studies, Faculty of Military Health Sciences, University of Defence, Hradec Králové, Czech Republic

Received 23rd June 2009. Revised 10th September 2009. Published online 8th December 2009.

Summary

In this in vitro study, using the HPLC method, we determined the ability of acetylcholinesterase (AChE) reactivators, used clinically, to penetrate the blood-brain barrier (BBB). We evaluated pralidoxime, HI-6, obidoxime, trimedoxime and methoxime – reactivators varying in the position of the oxime group on the pyridinium ring and linker connecting the pyridinium rings. Our results indicated that pralidoxime, a monoquaternary AChE reactivator, was the oxime with the most penetration. Molecular weight seems to be the most important factor for passive transport through the BBB. From the structural perspective, the connecting linker also plays a key role in the ability of the reactivators to penetrate the CNS. In this case, the simple and short linker is favorable for permeation of these compounds. The location of the oxime group on the pyridine ring may also influence passive transport into the brain; the best position of the oxime group seems to be position four.

Key words: blood-brain barrier; CNS penetration; HI-6; obidoxime; HPLC; oxime

INTRODUCTION

The basis of the current standard treatment of organophosphate (OP) poisoning is the administration of cholinesterase reactivators (Eyer 2003, Musílek et al. 2007). These include standard oximes with a similar basic structure but differing in the number of pyridinium rings, in the position of the oxime group on the pyridinium ring and in the linker connecting the pyridinium rings (Kuča et al. 2006). Some mono- and also bisquaternary pyridinium oximes are more or less frequently used in clinical practice. Pralidoxime, obidoxime, trimedoxime, methoxime and HI-6 are typical members of this family (Kuča et al. 2007). The mechanism of their action is hydrolytical cleaving of the OP from acetylcholinesterase (AChE; 3.1.1.7), restoring its enzymatic function. This reactivation of the inhibited enzyme is dependent on the type of OP and, on the reactivator used (Bajgar 2004, Žďárová Karasová et al. 2009).

Reactivation of AChE in the peripheral and also in the central nervous system (CNS) is very important for the survival of an organism poisoned with OP. The question of their penetration through the blood brain barrier (BBB) as well as the possibility of their achievement of effective brain concentration is under discussion (Bajgar et al. 2007a).
There is direct and indirect evidence for the ability of oximes to penetrate the BBB. The indirect evidence is based on AChE reactivation in the brain following OP intoxication (Bajgar et al. 1972, Kassa et al. 2007, Žďárová Karasová et al. 2008). The direct evidence for presence of oximes in the brain has been demonstrated by Sakurada et al. (2003) using microdialysis detection of pralidoxime. Similar observations have been described by other authors (Falb and Erdmann 1969, Cassel et al. 1997, Lorke et al. 2007, Petroianu et al. 2007).

The main aim of this study is to predict the extent of BBB penetration by standard AChE reactivators. Immobilized artificial membrane (IAM) chromatography was utilized for the assessment of these pharmacokinetic properties of the different oximes (Yoon et al. 2006). The method was validated on a set of 21 structurally varying therapeutics and subsequently applied to clinically used monoquaternary (pralidoxime) and bisquaternaly AChE reactivators (obidoxime, trimedoxime, HI-6 and methoxime).

MATERIALS AND METHODS

Chemicals
Atenolol, β-estradiol, caffeine, cefuroxime, chlorpromazine, cimetidine, corticosterone, desipramine, enalapril, hydrocortisone, ibuprofen, imipramine, lomefloxacin, loperamide, nadolol, piroxicam, progesterone, promazine, propranolol, and testosterone were purchased from Sigma Aldrich (Steinheim, Germany). Acetonitrile gradient grade LiChrosolv was purchased from Merck (Darmstadt, Germany). KH2PO4, Na2HPO4, KCl, and NaCl were purchased from Lachema (Neratovice, The Czech Republic). AChE reactivators were synthesized earlier in our laboratory (Musílek et al. 2006, Kuča et al. 2008). Water was reverse osmosis pure.

Apparatus
The HPLC system consisted of a P200 gradient pump (Spectra-Physics Analytical, Fremont, USA), a 7125 injection valve – 10 μl loop (Rheodyne, Cotati, USA), an UV1000 detector (Spectra-Physics Analytical, Fremont, USA) and a CSW Chromatography Station 1.5 software (DataApex, Praha, Czech Republic).

Chromatographic condition
Conditions for prediction (analysis)
An IAM.PC.DD 2 (150 × 4.6 mm; 12 μm) column (Regis Technologies, Morton Grove, USA) was used for analysis. The mobile phase was 80% PBS and 20% acetonitrile (v/v) with pH adjusted to 5.5 and 7.0 using Na2HPO4. The phosphate-buffered saline (PBS) was prepared with 2.7 mM KCl, 1.5 mM KH2PO4, 137 mM NaCl, and 8.1 mM Na2HPO4. It was delivered isocratically at a flow-rate of 1 ml/min. The absorbance was measured at 210 nm. All chromatograms were obtained at 37 °C.

Results
The most important coefficient for the determination of IAM partition is kIAM (IAM capacity factor), which was calculated as

\[ k_{IAM} = \frac{(t_r - t_0)}{t_0} \]

where \( t_r \) is the retention time of the drug and \( t_0 \) is the hold up time of the column.

In this study, the kIAM was determined for twenty-one reference drugs. The kIAM values were determined with a mobile phase of pH 7.4, although Yoon has recommended using a mobile phase of pH 5.5 because it provided better results. Our experiment was, however, carried out with a mobile phase of a higher pH because of the need to establish an environment similar to that in human body. This change of pH range may have markedly changed the state of the chemical ionization of the drugs. Chemical ionization is a very important factor which may in turn significantly change the possibility of molecule penetrating through the BBB.

According to Yoon et al. (2006) the assortment of drugs which can cross the BBB (CNS+) and those which do not penetrate into the brain (CNS−) was chosen based on kIAM corrected by the molecular weight (MW). The assortment of pH 7.4 was most successful with the power function of the molecular weight set at 4 (Yoon et al. 2006). The designated formula was:

\[ X = \frac{k_{IAM}}{MW^4} \times 10^{10}. \]
In addition a calculation was made of the predicted constants of the synthesized compounds – the partition coefficient (LogP), the molecular polar surface area (PSA) and the molecular weight (MW). In respect of LogP, it can be clearly seen that all substances are more soluble in water than in octanol. Fig. 1 illustrates the correlation between log P and log P and \( k_{IAM}/MW^4 \), the correlation coefficient \((r^2)\) being 0.6677 at pH 7.4.

The PSA (the sum of surfaces of polar atoms: oxygens, nitrogens and attached hydrogens, in a molecule) is a parameter very useful for the prediction of drug transport properties (Zhu et al. 2002). The PSA has been previously shown to correlate with human intestinal absorption (Palm et al. 1998, Clark 1999). When PSA is applied to a larger and more diverse compound set, however, outliers become more frequent (Zhu et al. 2002). In this study, a good correlation was observed between PSA and \( k_{IAM}/MW^4 \) with a correlation of 0.7199 at the mobile phase of pH of 7.4 (Fig. 2).

The CNS-drugs showed evident inability to bind to the phosphatidylcholine column and have X values less than 0.50, whereas the CNS+ drugs bound much better and their X values were distinctively higher than 1.00.

The utility of the optimized prediction method was examined for five reactivators of AChE, commonly used in therapy, which differ in their chemical structure (Table 1). At Fig. 3 is a HPLC chromatogram of the commonly used reactivators (pralidoxime, obidoxime, trimedoxime, HI-6, methoxime) with different retention times.
DISCUSSION

There are many questions still to be answered which are focused on the presence of reactivators in the brain. It has generally been accepted that oximes as quaternary compounds are not able to penetrate the BBB (Kassa et al. 2008). As already written above, there is much direct and indirect evidence for the ability of oximes to pass through into the brain (Falb and Erdmann 1969, Cassel et al. 1997, Lorke et al. 2007, Petroianu et al. 2007).

The AChE reactivation is very important in CNS, because there are so many changes in the physiology of the brain after OP intoxication (Kuča and Kassa 2004). They cause a strong cholinesterase inhibition with subsequent changes in the level of neurotransmitters including acetylcholine and catecholamines (Bajgar et al. 2007b). Also recorded in CNS were changes in membrane permeability, in the influence of BBB permeability and in metabolic imbalances (changes in the brain energy metabolism during soman intoxication, influence of the oxidative metabolism and ATP level in the brain) (Gupta 2004).

The pontomedullar area, where respiration is regulated (controlled by cholinergic neurons) is of particular importance. Depression of the central respiratory control centres in the pontomedullar area is considered as a primary event leading to death (Goswany et al. 1994, Sungur and Guven 2001, Kubin and Fenik 2004). When the AChE reactivation is present in this area, a good therapeutic effect is observed. The survival of intoxicated animals is correlated with AChE activity in the pontomedullar area (Bajgar et al. 2007b).

According to our hypothesis, the results obtained in our study proved a dependency between CNS penetration and the structure of various reactivators. The less penetrative bisquaternary compounds were HI-6 and obidoxime. Oxime HI-6, is a very promising antidote against the broad spectrum of OP (Kuča et al. 2009). Obidoxime is effective against tabun and pesticide intoxications. There are three differences in the chemistry of these clinically used oximes. The position of the oxime group on the pyridinium ring is the first (obidoxime – 4, HI-6 – 2 position). Then, obidoxime has two oxime groups of HI-6 instead of one. Finally, the second obidoxime oxime group is replaced by the carbamoyl group in the HI-6 structure.

If these results are compared with those of trimedoxime, it can clearly be seen that the difference in the connecting linker also influences BBB penetration. The oxygen in the linker between two pyridinium rings is not conducive to BBB permeation. The best bisquaternary structure from our point of view is methoxime which has two oxime groups in the position four on the pyridinium rings and very short linker without oxygen.

It is known that the most important parameters of influence in BBB passive penetration are MW and the presence of sufficient liposolubility (Bellawance et al. 2007).
This was confirmed also in our study. The oxime with lowest MW (monooquaternary AChE reactivator, pralidoxime) was the best penetrating structure (Žďárová Karasová et al. 2010). Our results were indirectly confirmed in other in vivo studies, (Lorke et al. 2007, 2008, Petroianu et al. 2007, Kalász et al. 2009). The monooquaternary oximes penetrated 10 times more than bisquaternary compounds.

On the basis of our results we can predict the more permeating oxime structures. This knowledge may be useful in the synthesis of more effective AChE reactivators.

CONCLUSION

In conclusion, we have tested an HPLC method with UV detection for the prediction of five clinically used AChE reactivators. According to our results molecular weight seems to be the most important factor for passive transport through the BBB. Secondly, based on results obtained, even small changes in the chemical structure of oxime (connecting linker, location of oxime group on the pyridinium ring and also substitution of oxime group) are important in influencing the extent of brain penetration.

ACKNOWLEDGEMENT

Authors would like to thank to the Ministry of Health (Czech Republic) – “The Evaluation of Penetration of Different Acetylcholinesterase Reactivators through Blood-Brain Barrier”. Thanks are due to Mrs. M. Hrabinová for skilled technical assistance.

REFERENCES

Bellawance MA, Blanchette M, Fortin D: Recent advances in blood-brain barrier disruption as a CNS delivery strategy. AAPS J 10:166–177, 2008.


